Fig. S2


C-MYC
medium
isotype
Emab
fold increase [AU]
0
4
8
12
16
20
untreated
R848
anti-IgM
anti-IgM + R848
BCLXL
medium
isotype
Emab
fold increase [AU]
0
2
4
6
8
10
untreated
R848
anti-IgM
anti-IgM + R848
TLR9
medium
isotype
Emab
fold increase [AU]
0
2
4
6
8
untreated
R848
anti-IgM
anti-IgM + R848
TLR7
medium
isotype
Emab
fold increase [AU]
0
2
4
6
8
untreated
R848
anti-IgM
anti-IgM + R848
MyD88
medium
isotype
Emab
fold increase [AU]
0
2
4
6
8
untreated
R848
anti-IgM
anti-IgM + R848
IRF7
medium
isotype
Emab
fold increase [AU]
0
2
4
6
8
10
untreated
R848
anti-IgM
anti-IgM + R848